FDA Approves Anthim Injection to Treat Inhalational Anthrax

March 24, 2016

  • FDA approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs.

  • Anthim carries boxed warning that drug can cause allergic reactions, including a severe reaction called anaphylaxis.

  • Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.